Drug or Treatment Category: Endocrine (Hormone) Therapy

NCT05090358: Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

NCT05090358
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone Therapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior chemotherapy in the metastatic setting; Patients with Type 1 diabetes mellitus or Type 2 diabetes mellitus requiring treatment with a sulfonylurea, meglitinide, SGLT2 inhibitors, or insulin
https://ClinicalTrials.gov/show/NCT05090358

NCT05095207: Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

NCT05095207
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+, AR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 90 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic untreated brain metastases or leptomeningeal disease – see trial for details; Patients currently taking endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane, oral contraceptive pills)
https://ClinicalTrials.gov/show/NCT05095207

Up ↑